Movies love a good distraction. While you’re watching the action, something subtle plays out in the corner. That quiet thing ...

NEW YORK – XyloCor Therapeutics on Thursday said it has treated the first patient with XC001 (encoberminogene rezmadenovec), its gene therapy for coronary artery disease and refractory angina, within ...

Team prepares for commercialization bolstered by START Program and regulatory recognition NEW YORK, July 8, 2025 /PRNewswire/ -- Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering ...

A new gene therapy trial safely restores hearing in deaf children and adults, offering hope for those with DFNB9 deafness once thought untreatable.

Abbvie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, the companies announced Monday. The acquisition will hand AbbVie access to technology ...